title: CD38-Targeted Immunochemotherapy in Refractory Multiple Myeloma: A New Horizon.
abstract: CD38 is a type II transmembrane glycoprotein that is highly expressed in multiple myeloma and is a promising target for immunotherapy. Daratumumab is a human monoclonal antibody that has potent anti-multiple myeloma activity both as monotherapy and in combination with other multiple myeloma treatments, and has breakthrough designation on this basis.
authors: Jerome Lipper Multiple Myeloma Center, Division of Hematologic Malignancy, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
authors: Jacob P
authors: JP
authors: Laubach
authors: Jerome Lipper Multiple Myeloma Center, Division of Hematologic Malignancy, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts. paul_richardson@dfci.harvard.edu.
authors: Paul G
authors: PG
authors: Richardson
mesh_terms: D051997:ADP-ribosyl Cyclase 1 / Q000037:antagonists & inhibitors* / Q000378:metabolism*; D000818:Animals; D000069286:Bortezomib / Q000494:pharmacology*; D005260:Female; D006801:Humans; D000077269:Lenalidomide; D008297:Male; D009101:Multiple Myeloma / Q000276:immunology* / Q000378:metabolism*; D013792:Thalidomide / Q000031:analogs & derivatives* / Q000494:pharmacology
chemical_list: D013792:Thalidomide; D000069286:Bortezomib; D051997:ADP-ribosyl Cyclase 1; D000077269:Lenalidomide